Predicting the Efficacy of Dienogest in Patients With Endometriosis Using MRI

What this Trial Is About

This research aims to understand whether MRI scans can predict how women with endometriosis respond to treatment with dienogest. Endometriosis is a common condition causing chronic pelvic pain and reduced quality of life. Although dienogest is commonly used, responses to this medication vary between individuals. The study focuses on whether initial MRI features of endometriotic lesions relate to improvements in pelvic pain and help identify patients likely to benefit from dienogest. Participants are women diagnosed with endometriosis and prescribed dienogest as part of their usual care. The study is observational, meaning no additional treatments are assigned. Participants will have routine MRI scans and clinical follow-ups while taking dienogest. Data on pelvic pain, quality of life, and MRI changes will be collected over 12 months to analyze treatment response. During the study, participants will regularly assess their pelvic pain using a visual scale and complete quality of life questionnaires. Researchers will also monitor MRI changes in endometriotic lesions over the year. The main outcome is the change in pelvic pain severity from treatment start to 12 months. Secondary outcomes include quality of life improvements and MRI characteristic changes, helping to understand dienogests effects and MRIs predictive value.

MRI-Based Prediction of Dienogest Response in Endometriosis